SynthesisFrontiers in pharmacology2025
Therapeutic potential of modified Yukgunja-tang (Liujunzi Decoction, Rikkunshito) as an adjuvant treatment for lung cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Yukgunja-tang (YGJT), also known as Liujunzi Decoction or Rikkunshito, is a traditional East Asian herbal formula widely used to manage symptoms associated with cancer and chemotherapy. This study aimed to systematically evaluate the efficacy and safety of modified YGJT combined with standard antitumor therapy in patients with lung cancer. Methods: A comprehensive search was conducted in 10 databases through March 2025. Randomized controlled trials comparing modified YGJT plus antitumor therapy versus antitumor therapy alone or placebo were included. Studies involving other herbal combinations or East Asian therapies were excluded. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. A random-effects model was used for meta-analysis. Results: Thirty-one trials involving 2,496 participants were included. Modified YGJT significantly improved the objective response rate (ORR; RR 1.69, 95% CI 1.41-2.04), disease control rate (DCR; RR 1.21, 95% CI 1.11-1.31), and Karnofsky Performance Status (KPS; RR 1.79, 95% CI 1.23-2.60; MD 8.62, 95% CI 3.86-13.38). Symptom relief was observed (RR 1.52, 95% CI 1.25-1.85; MD -10.87, 95% CI -12.51 to -9.22), along with improvements in immune markers (CD3 Conclusion: Modified YGJT may offer clinical benefits as an adjuvant to standard lung cancer therapy by improving treatment outcomes and reducing toxicity. Large-scale, high-quality trials are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024619038, identifier CRD42024619038.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.